Publications
70
Citations
772
Est. group size
—
Recurring co-author estimate
Active years
28
Publishing since 1999
Misty Dawn Shields studies lung cancer, with a strong focus on small cell lung cancer (SCLC), a fast-growing and aggressive type of lung tumor. The research examines how immunotherapy (treatments that use the immune system to fight cancer) and newer drugs work in patients, and looks for biomarkers that predict which patients will respond. Much of the work combines real-world patient outcomes, clinical trials, and laboratory studies of tumor biology.
Publication activity has grown sharply in recent years, rising from a few papers annually to over twenty in 2025.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~10 · 6% small-team papers (≤3 authors) · across 22 venues
- Monalizumab plus durvalumab plus platinum-based chemotherapy for first-line treatment of extensive stage small-cell lung cancer: Early efficacy results from MOZART trial.
Journal of Clinical Oncology · 2026
- NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026
Journal of the National Comprehensive Cancer Network · 2026
- ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin
Molecular Cancer Therapeutics · 2026
- SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer
Lung Cancer · 2026
- Prognostic Significance and Biomarker Identification by Progression Patterns in Patients With Small Cell Lung Cancer After Immune Checkpoint Inhibitors
Clinical Lung Cancer · 2026
- Comparison by immunotherapy agent of real-world outcomes with chemoimmunotherapy in first-line extensive-stage small cell lung cancer.
Journal of Clinical Oncology · 2026
- Demographics and outcomes of individuals with young-onset small cell lung cancer.
Journal of Clinical Oncology · 2026
- Impact of lung cancer screening in patients diagnosed with small cell lung cancer.
Journal of Clinical Oncology · 2026
- A new era of immunotherapy: Comparison of real-world outcomes in limited-stage small cell lung cancer.
Journal of Clinical Oncology · 2026
- A first-in-human phase 1a study of LP-184, a tumor site–activated novel alkylating agent, in patients with advanced solid tumors.
Journal of Clinical Oncology · 2026
- Immunotherapy for uncommon EGFR mutations in lung adenocarcinoma.
Journal of Clinical Oncology · 2026
- Clinicogenomic characteristics associated with non-durable response to first-line immunotherapy among advanced lung squamous cell carcinoma with PD-L1 ≥ 50%.
Journal of Clinical Oncology · 2026
- Supplementary Table S3 from ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin
2026
- Supplementary Figure S3 from ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin
2026
- Supplementary Figure S6 from ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin
2026
- Journal of Clinical Oncology×17
- Journal of Thoracic Oncology×5
- Journal of the National Comprehensive Cancer Network×5
- Clinical Lung Cancer×3
- SSRN Electronic Journal×3
- Jing Su
Medicine · Indiana University
- Logan Roof
Medicine · The Ohio State University
- D. Carbone
Medicine · The Ohio State University
- Carly Pilcher
Medicine · The Ohio State University
- Allison Schepers
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile